Mounjaro vs Wegovy: Which PGD Workflow Should Your Pharmacy Prioritise in 2026?

1.Why This Decision Matters for Community Pharmacies in 2026

Weight-loss injections have moved from niche prescribing territory into one of the most in-demand services a community pharmacy can offer. Patients are actively searching for local pharmacies that stock Mounjaro and Wegovy, GPs are increasingly directing patients toward specialist and community-based pathways, and NHS England has set clear rollout targets that put pharmacies at the centre of delivery. For independent pharmacies weighing up where to invest consultation time, staff training, and stock budget, the decision between prioritizing Mounjaro, Wegovy, or running both isn’t just clinical; it’s operational.

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both GLP-1-based medicines, but they are not interchangeable in either their clinical profile or their commissioning pathway. Mounjaro mimics two hormones instead of one, Wegovy carries a distinct cardiovascular risk-reduction license that Mounjaro does not have, and each comes with its own eligibility thresholds, monitoring requirements, and PGD documentation needs. Getting this decision right in 2026 means understanding not just which drug is more effective, but which one fits your patient demographic, your consultation capacity, and the referral pathways feeding into your pharmacy.

This guide draws on current NICE-aligned clinical guidance to walk through both medicines and help your pharmacy build, or refine, a PGD workflow that is safe, compliant and sustainable.

2.Mounjaro (Tirzepatide): How It Works and Who It’s For

Mounjaro is a once-weekly, self-administered injection built around the active ingredient tirzepatide. Unlike older weight-loss medicines that work on a single hormone pathway, tirzepatide mimics two separate hormones, GLP-1 and GIP, both of which play a role in reducing appetite and increasing feelings of fullness after eating. This dual-action mechanism is part of why tirzepatide has drawn so much clinical and commercial attention over the past two years.

The effectiveness data backs this up. Research published in 2025 found that people taking tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared with 13.7% for people taking semaglutide over the same period. For pharmacies fielding patient questions about “which injection works better,” this is often the headline figure patients have already seen online, and it’s worth having a clear, accurate answer ready at the counter.

From an eligibility and commissioning standpoint, NICE has recommended tirzepatide for weight management in adults living with obesity who also present with at least one other weight-related health problem. These conditions include abnormal blood fat levels (dyslipidemia), high blood pressure, obstructive sleep apnea, cardiovascular disease, and type 2 diabetes. Since March 2025, tirzepatide can only be initiated through a specialist weight management service where a healthcare professional confirms it’s the right treatment and where the wider clinical team, including dietitians and psychologists, can offer wraparound support.

The primary care and community rollout is being phased deliberately. Initially, only patients with the highest clinical need are eligible, specifically those with four or more of the listed weight-related conditions and a BMI of 40 or above, adjusted for ethnicity. NHS England has set a target of extending tirzepatide access to 220,000 people by the end of 2027, delivered through a mix of specialist clinics, GP surgeries, and community settings that also provide dietary and physical activity support. This phased approach means pharmacy teams need to stay closely aligned with their local integrated care board’s current eligibility rules, since access criteria can shift as the rollout progresses and NICE completes its three-year review of the initial implementation.

3. Wegovy (Semaglutide): How It Works and Who It’s For

Wegovy is also a once-weekly injection, but it works through a single hormone pathway, mimicking GLP-1 to slow digestion, reduce appetite, and help patients feel fuller for longer after eating. Semaglutide has a longer track record in UK prescribing than tirzepatide, having first been approved for weight loss by NICE back in 2023, and it’s also prescribed under the brand name Ozempic for type 2 diabetes management, which means many patients and prescribers already have some familiarity with how it behaves.

Access to semaglutide for weight management currently runs exclusively through specialist weight management services, typically after a patient has already tried diet and exercise changes without sufficient success. Eligibility is BMI-led: patients may be prescribed Wegovy if they have weight-related health problems and a BMI of 35 or above or 32.5 or above for those of Asian, Chinese, Middle Eastern, Black African, or African-Caribbean origin. A second tier of eligibility covers patients with a BMI of 30 to 34.9 (or 27.5 to 32.4 for the same ethnic groups) who also meet additional criteria for referral to a specialist weight-loss clinic.

What sets Wegovy apart clinically, and what every pharmacy team should know when advising patients or liaising with prescribers, is its cardiovascular risk-reduction license. In April 2026, NICE recommended semaglutide, alongside dietary and activity changes, specifically to reduce the risk of heart attack, stroke, or death from heart disease in people with a BMI of 27 or above who have already had a heart attack, a stroke, or symptomatic peripheral arterial disease. This recommendation was based on a major clinical trial of more than 17,000 people with existing cardiovascular disease, which found that those taking semaglutide were 20% less likely to have a heart attack, stroke, or die from coronary heart disease than those on a placebo injection over almost three years. Mounjaro does not currently hold an equivalent cardiovascular indication, which makes this a genuinely distinguishing factor rather than a marginal one.

Another practical difference worth flagging in a PGD workflow: there is no fixed time limit on Wegovy prescribing for cardiovascular risk reduction, meaning eligible patients can continue treatment for as long as it’s judged clinically appropriate, whereas the general obesity pathway through specialist weight clin3ics is typically time-limited to around two years.

4.Comparing the Two PGDs Side by Side

When you strip both medicines back to their operational essentials, the workflows diverge in a few key ways.

Mounjaro’s workflow is built around comorbidity density. Patients are prioritized by how many weight-related conditions they present with, not just their BMI alone, which means intake forms and PGD screening need to capture a fuller clinical picture before a patient can be accepted onto the service. Dose titration also tends to involve more detailed counseling, since the dual hormone mechanism can produce a slightly different side-effect profile and adjustment pattern than a single-pathway medicine.

Wegovy’s workflow splits into two distinct tracks. One is the general obesity management route via specialist referral, governed by BMI thresholds. The other is the cardiovascular risk-reduction route, which has a lower BMI entry point, an open-ended treatment duration, and a different clinical justification that pharmacy staff need to be able to explain clearly to patients who may not realise they qualify through their cardiovascular history rather than their weight alone.

Both medicines share a common operational backbone: BMI and comorbidity verification against current thresholds, a structured first consultation covering benefits, limitations and likely side effects, an ongoing supply and dose-review schedule, and defined escalation routes for adverse effects. Where they differ is in the detail of who qualifies, how long they can stay on treatment, and what specific counselling points need to be documented at each stage.

5.Consultation, Monitoring and Safety-Netting Considerations

Regardless of which medicine your pharmacy prioritizes, a handful of clinical safety points need to be built into every PGD consultation and every follow-up review.

Digestive side effects are the most commonly reported issue with both medicines. Feeling sick, diarrhea, constipation, and stomach pain affect around 1 in 10 people taking either drug. Setting expectations clearly at the first consultation, and having an agreed pathway for dose adjustment or discontinuation if symptoms become severe, reduces both patient dropout and avoidable escalation to urgent care.

Pancreatitis risk needs to be part of every safety-netting conversation, not just the initial consultation. Up to 1 in 100 people taking either drug may develop acute pancreatitis, and patients need clear, repeated guidance to seek urgent medical attention for sudden, severe abdominal pain.

Contraception counselling is essential, particularly for Mounjaro. Patients taking tirzepatide who also rely on the contraceptive pill should be advised to use an additional method of contraception, such as a condom, because absorption of the pill may be reduced while using Mounjaro. The same principle extends to HRT: patients on tirzepatide who use oral HRT should be advised to consider patches or gels instead, since oral absorption may also be affected.

Pre-surgical disclosure should be a standard prompt in patient records and consultation scripts. Anyone due to undergo a surgical procedure should inform their full healthcare team, including the anesthesiologist, if they are taking liraglutide, semaglutide, or tirzepatide.

Pregnancy, planned pregnancy, and breastfeeding exclusions apply to both medicines and should be reconfirmed at every review appointment, not assumed to be static from the initial consultation.

Lifestyle support cannot be treated as optional add-on advice. NICE guidance recommends a reduced-calorie diet and regular physical activity, including resistance training, alongside these injections, because research shows weight-loss injections can lead to a loss of muscle mass as well as fat. Pharmacies that build structured dietary and activity guidance into their service, rather than leaving it to a leaflet, are better aligned with NICE quality standards and tend to see stronger patient retention and satisfaction.

Post-discontinuation support is where many services fall short and where the evidence is clearest about the risk of relapse. A 2026 meta-analysis found that patients who stopped taking these medicines regained weight considerably faster than those who lost weight through behavioural programs alone, which is why NICE recommends offering structured support for at least a year after stopping weight-loss injections, including regular check-ups and practical advice to help maintain results.

6.Operational and Business Considerations for Pharmacy Teams

Beyond the clinical detail, there are practical staffing and workflow questions that should shape which service your pharmacy prioritizes. Consultation length is one of the biggest factors: Mounjaro’s fuller comorbidity screening and dual-mechanism counselling generally take longer per patient than a straightforward BMI-based Wegovy intake, which has knock-on effects for appointment scheduling and staff rota planning.

Stock and cold-chain management also differ slightly given the two products’ differing dosing pens and titration schedules, so pharmacies running both services need clear, separate protocols to avoid dispensing errors. Staff training investment should reflect which patient population you expect to serve most; if your catchment area has a higher concentration of patients with existing cardiovascular disease, prioritising Wegovy’s risk-reduction pathway may deliver more value per consultation hour than a broader obesity-only offering.

Finally, documentation load under each PGD is non-trivial, and getting it wrong carries real compliance risk. Building templated, auditable consultation records for each pathway from the outset saves significant admin time as patient volumes grow through 2026.

7.Which Workflow Should Your Pharmacy Prioritise?

There’s no single right answer; it depends on your patient population, referral pathways, and consultation capacity.

Prioritise Mounjaro if your pharmacy serves a higher proportion of patients with multiple weight-related comorbidities and higher BMI ranges and if you’re positioned within a local high-need rollout cohort. Be prepared for slightly longer, more detailed dose-titration conversations given its dual hormone mechanism.

Prioritise Wegovy if your patient base includes people with existing cardiovascular disease who could benefit from the dedicated risk-reduction pathway, which has a lower BMI entry point and no fixed treatment duration. This pathway is likely to grow in relevance through 2026 as more prescribers and patients become aware of the updated NICE recommendation.

Run both in parallel if your pharmacy has the consultation capacity and staff training to manage two distinct eligibility pathways cleanly. Many independent pharmacies are finding that offering both services, with clearly differentiated intake criteria and separate documentation, captures a wider referral base without compromising consultation quality or compliance.

8.How PharmaEscalator Supports Weight-Management PGD Services

Running a compliant, well-documented PGD service for weight-loss injections takes more than clinical knowledge; it needs the right patient-facing systems, GDPR-compliant intake and follow-up processes, and a local visibility strategy that helps eligible patients actually find your pharmacy. PharmaEscalator works with independent community pharmacies to build the digital infrastructure around private and NHS-commissioned services like these, from search-optimized service pages that explain eligibility clearly to patients researching their options, to SMS-based repeat prescription and follow-up reminders that support the ongoing monitoring these treatments require. If your pharmacy is weighing up how to prioritise Mounjaro, Wegovy, or both, PharmaEscalator can help you turn that clinical decision into a workflow patients can find, trust and stay engaged with, right through to their post-discontinuation follow-up.

Frequently Asked Questions